Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus

Journal of Virology

Volumn 82, Issue 2, 2008, Pages 966-973

  Meunier, Jean Christophe ^a   Russell, Rodney S ^a   Goossens, Vera ^b   Priem, Sofie ^b   Walter, Hugo ^b   Depla, Erik ^b   Union, Ann ^b   Faulk, Kristina N ^a   Bukh, Jens ^a,c,d   Emerson, Suzanne U ^a   Purcell, Robert H ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b GENimmune   (Belgium)

^c Mental Health Services CPH   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; GLYCOPROTEIN E1; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN;

AMINO ACID SEQUENCE; ANTIBODY ISOLATION; ARTICLE; CELL CULTURE; CELLULAR IMMUNITY; CONTROLLED STUDY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INFECTION CONTROL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; VIRUS PARTICLE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; EPITOPE MAPPING; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HUMANS; MICE; NEUTRALIZATION TESTS; PAN TROGLODYTES; VIRAL ENVELOPE PROTEINS;

HEPATITIS C VIRUS;

EID: 37849010852     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01872-07     Document Type: Article

References (42)

1. Bartosch, B., J. Bukh, J. C. Meunier, C. Granier, R. E. Engle, W. C. Blackwelder, S. U. Emerson, F. L. Cosset, and R. H. Purcell. 2003. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc. Natl. Acad. Sci. USA 100:14199-14204.
2. Bartosch, B., J. Dubuisson, and F. L. Cosset. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197:633-642.
3. Bowen, D. G., and C. M. Walker. 2005. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436:946-952.
4. Bukh, J., R. H. Purcell, and R. H. Miller. 1993. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Proc. Natl. Acad. Sci. USA 90:8234-8238.
5. Choo, Q. L., G. Kuo, R. Ralston, A. Weiner, D. Chien, G. Van Nest, J. Han, K. Berger, K. Thudium, C. Kuo, et al. 1994. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. USA 91:1294-1298.
6. Depraetere, S., L. Verhoye, G. Leclercq, and G. Leroux-Roels. 2001. Human B cell growth and differentiation in the spleen of immunodeficient mice. J. Immunol. 166:2929-2936.
7. Dreux, M., T. Pietschmann, C. Granier, C. Voisset, S. Ricard-Blum, P. E. Mangeot, Z. Keck, S. Foung, N. Vu-Dac, J. Dubuisson, R. Bartenschlager, D. Lavillette, and F. L. Cosset. 2006. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J. Biol. Chem. 281:18285-18295.
8. El-Awady, M. K., A. A. Tabll, K. Atef, S. S. Yousef, M. H. Omran, Y. El-Abd, N. G. Bader-Eldin, A. M. Salem, S. F. Zohny, and W. T. El-Garf. 2006. Antibody to E1 peptide of hepatitis C virus genotype 4 inhibits virus binding and entry to HepG2 cells in vitro. World J. Gastroenterol. 12:2530-2535.
9. Eren, R., D. Landstein, D. Terkieltaub, O. Nussbaum, A. Zauberman, J. Ben-Porath, J. Gopher, R. Buchnick, R. Kovjazin, Z. Rosenthal-Galili, S. Aviel, E. Ilan, Y. Shoshany, L. Neville, T. Waisman, O. Ben-Moshe, A. Kischitsky, S. K. Foung, Z. Y. Keck, O. Pappo, A. Eid, O. Jurim, G. Zamir, E. Galun, and S. Dagan. 2006. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J. Virol. 80:2654-2664.
10. European Association for the Study of the Liver. 1999. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J. Hepatol. 31(Suppl. 1):3-8.
11. Farci, P., H. J. Alter, D. C. Wong, R. H. Miller, S. Govindarajan, R. Engle, M. Shapiro, and R. H. Purcell. 1994. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc. Natl. Acad. Sci. USA 91:7792-7796.
12. Farci, P., A. Shimoda, D. Wong, T. Cabezon, D. De Gioannis, A. Strazzera, Y. Shimizu, M. Shapiro, H. J. Alter, and R. H. Purcell. 1996. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. USA 93:15394-15399.
13. Féray, C., M. Gigou, D. Samuel, B. Ducot, P. Maisonneuve, M. Reynes, A. Bismuth, and H. Bismuth. 1998. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann. Intern. Med. 128:810-816.
14. Grollo, L., J. Torresi, H. Drummer, W. Zeng, N. Williamson, and D. C. Jackson. 2006. Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes. Antivir. Ther. 11:1005-1014.
15. Hsu, M., J. Zhang, M. Flint, C. Logvinoff, C. Cheng-Mayer, C. M. Rice, and J. A. McKeating. 2003. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. USA 100:7271-7276.
16. Ishida, C., K. Matsumoto, K. Fukada, K. Matsushita, H. Shiraki, and Y. Maeda. 1993. Detection of antibodies to hepatitis C virus (HCV) structural proteins in anti-HCV-positive sera by an enzyme-linked immunosorbent assay using synthetic peptides as antigens. J. Clin. Microbiol. 31:936-940.
17. Ishii, K., D. Rosa, Y. Watanabe, T. Katayama, H. Harada, C. Wyatt, K. Kiyosawa, H. Aizaki, Y. Matsuura, M. Houghton, S. Abrignani, and T. Miyamura. 1998. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 28:1117-1120.
18. Keck, Z. Y., T. K. Li, J. Xia, B. Bartosch, F. L. Cosset, J. Dubuisson, and S. K. Foung. 2005. Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J. Virol. 79:13199-13208.
19. Keck, Z. Y., V. M. Sung, S. Perkins, J. Rowe, S. Paul, T. J. Liang, M. M. Lai, and S. K. Foung. 2004. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J. Virol. 78:7257-7263.
20. Knodell, R. G., M. E. Conrad, A. L. Ginsberg, and C. J. Bell. 1976. Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis. Lancet i:557-561.
21. Kuiken, C., K. Yusim, L. Boykin, and R. Richardson. 2005. The Los Alamos hepatitis C sequence database. Bioinformatics 21:379-384.
22. Leroux-Roels, G., A. H. Batens, I. Desombere, B. Van Den Steen, C. Vander Stichele, G. Maertens, and F. Hulstaert. 2005. Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. Hum. Vaccin. 1:61-65.
23. Leroux-Roels, G., E. Depla, F. Hulstaert, L. Tobback, S. Dincq, J. Desmet, I. Desombere, and G. Maertens. 2004. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 22:3080-3086.
24. Lindenbach, B. D., M. J. Evans, A. J. Syder, B. Wolk, T. L. Tellinghuisen, C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and C. M. Rice. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626.
25. Logvinoff, C., M. E. Major, D. Oldach, S. Heyward, A. Talal, P. Balfe, S. M. Feinstone, H. Alter, C. M. Rice, and J. A. McKeating. 2004. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 101:10149-10154.
26. Maertens, G., and L. Stuyver. 1997. Genotypes and genetic variation of hepatitis C virus, p. 182-233. In A. Zuckerman and T. Harrison (ed.), Molecular medicine of hepatitis. Molecular medical science series. Wiley, Chichester, United Kingdom.
27. Mast, E. E., M. J. Alter, and H. S. Margolis. 1999. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 17:1730-1733.
28. Meunier, J. C., R. E. Engle, K. Faulk, M. Zhao, B. Bartosch, H. Alter, S. U. Emerson, F. L. Cosset, R. H. Purcell, and J. Bukh. 2005. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc. Natl. Acad. Sci. USA 102:4560-4565.
29. Orland, J. R., T. L. Wright, and S. Cooper. 2001. Acute hepatitis C. Hepatology 33:321-327.
30. Pestka, J. M., M. B. Zeisel, E. Blaser, P. Schurmann, B. Bartosch, F. L. Cosset, A. H. Patel, H. Meisel, J. Baumert, S. Viazov, K. Rispeter, H. E. Blum, M. Roggendorf, and T. F. Baumert. 2007. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. USA 104:6025-6030.
31. Pietschmann, T., A. Kaul, G. Koutsoudakis, A. Shavinskaya, S. Kallis, E. Steinmann, K. Abid, F. Negro, M. Dreux, F. L. Cosset, and R. Bartenschlager. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. USA 103:7408-7413.
32. Ray, R., A. Khanna, L. M. Lagging, K. Meyer, Q. L. Choo, R. Ralston, M. Houghton, and P. R. Becherer. 1994. Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus. J. Virol. 68:4420-4426.
33. Sällberg, M., U. Ruden, B. Wahren, and L. O. Magnius. 1993. Antigenic regions within the hepatitis C virus envelope 1 and non-structural proteins: identification of an IgG3-restricted recognition site with the envelope 1 protein. Clin. Exp. Immunol. 91:489-494.
34. Schofield, D. J., B. Bartosch, Y. K. Shimizu, T. Allander, H. J. Alter, S. U. Emerson, F. L. Cosset, and R. H. Purcell. 2005. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology 42:1055-1062.
35. Shimizu, Y. K., M. Hijikata, A. Iwamoto, H. J. Alter, R. H. Purcell, and H. Yoshikura. 1994. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J. Virol. 68:1494-1500.
36. Shimizu, Y. K., H. Igarashi, T. Kiyohara, T. Cabezon, P. Farci, R. H. Purcell, and H. Yoshikura. 1996. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 223:409-412.
37. Siemoneit, K., S. Cardoso Mda, K. Koerner, A. Wolpl, and B. Kubanek. 1995. Human monoclonal antibodies for the immunological characterization of a highly conserved protein domain of the hepatitis C virus glycoprotein E1. Clin. Exp. Immunol. 101:278-283.
38. Takaki, A, M. Wiese, G. Maertens, E. Depla, U. Seifert, A. Liebetrau, J. L. Miller, M. P. Manns, and B. Rehermann. 2000. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med. 6:578-582.
39. Takeuchi, K., Y. Kubo, S. Boonmar, Y. Watanabe, T. Katayama, Q. L. Choo, G. Kuo, M. Houghton, I. Saito, and T. Miyamura. 1990. Nucleotide sequence of core and envelope genes of the hepatitis C virus genome derived directly from human healthy carriers. Nucleic Acids Res. 18:4626.
40. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H. G. Krausslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
41. Westin, J., M. Lindh, L. M. Lagging, G. Norkrans, and R. Wejstal. 1999. Chronic hepatitis C in Sweden: genotype distribution over time in different epidemiological settings. Scand. J. Infect. Dis. 31:355-358.
42. Zhang, P., C. G. Wu, K. Mihalik, M. L. Virata-Theimer, M. Y. Yu, H. J. Alter, and S. M. Feinstone. 2007. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc. Natl. Acad. Sci. USA 104:8449-8454.